Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Travatan · 1 trial · 2 indications
Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken. All IOP measurements were performed with a Goldmann applanation tonometer.
| Arm | Type | Description |
|---|---|---|
| Travatan | EXPERIMENTAL | Travoprost (0.004%) |
| Name | Type | Description |
|---|---|---|
| Travatan | DRUG | Travoprost (0.004%) 1 drop each eye once daily |
Adult patients of any race and either sex with chronic angle-closure glaucoma.
Travatan is a small molecule used for the treatment of glaucoma and open-angle glaucoma, as well as ocular hypertension. It is administered once daily and is being developed for ophthalmic use. The drug is currently in Phase 3 clinical development.
Travatan is being developed by Alcon Inc., a company traded under the ticker symbol ALC. Alcon is conducting clinical trials to evaluate the safety and efficacy of Travatan for the treatment of glaucoma and open-angle glaucoma.
Travatan is in Phase 3 clinical development. It has completed one Phase 3 trial, which was a long-term safety study. The drug is investigational and has not been approved by regulatory authorities.
Travatan has one completed Phase 3 clinical trial, identified as NCT00051168. This study, titled 'A Long-term Safety Study of Once-daily Travatan,' enrolled 502 participants with glaucoma, open-angle glaucoma, or ocular hypertension in the United States.
Travatan is not FDA approved. It is an investigational drug currently in Phase 3 clinical development. A Phase 3 safety study has been completed, but the drug has not yet received regulatory approval for the treatment of glaucoma or open-angle glaucoma.